Notice Number: NOT-HL-16-464
Key Dates
Release Date: November 16, 2016
RFA-HL-15-030
Issued by
National Heart, Lung, and Blood Institute (NHLBI)
Purpose
The purpose of this Notice is to inform potential applicants of changes to RFA-HL-15-030 "Stem Cell-Derived Blood Products for Therapeutic Use: Technology Improvement (R43/R44)". The following sections of the Funding Opportunity Announcement have been updated to reflect a change in the final Application Due Date (from February 20, 2017 to July 20, 2017) as well as changes to the Award Information.
Part 1. Key Dates
Currently reads:
Posted Date |
November 6, 2014 |
Open Date (Earliest Submission Date) |
January 20, 2015 |
Letter of Intent Due Date(s) |
30 days prior to the application due date |
Application Due Date(s) |
February 20, 2015 (Phase I or Fast-Track); February 20, 2016 (Phase I; Phase II; or Fast-Track); February 20, 2017 (Phase II only), by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. |
AIDS Application Due Date(s) |
Not Applicable |
Scientific Merit Review |
June 2015, June 2016, June 2017 |
Advisory Council Review |
August 2015, August 2016, August 2017 |
Earliest Start Date |
September 2015, September 2016, September 2017 |
Expiration Date |
February 21, 2017 |
Due Dates for E.O. 12372 |
Not Applicable |
Modified to read:
Posted Date |
November 6, 2014 |
Open Date (Earliest Submission Date) |
January 20, 2015 |
Letter of Intent Due Date(s) |
30 days prior to the application due date |
Application Due Date(s) |
February 20, 2015 (Phase I or Fast-Track); February 20, 2016 (Phase I; Phase II; or Fast-Track); July 20, 2017 (Phase II only), by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. |
AIDS Application Due Date(s) |
Not Applicable |
Scientific Merit Review |
June 2015, June 2016, October 2017 |
Advisory Council Review |
August 2015, August 2016, January 2018 |
Earliest Start Date |
September 2015, September 2016, April 2018 |
Expiration Date |
July 21, 2017 |
Due Dates for E.O. 12372 |
Not Applicable |
Part 2. Section II. Award Information
Funds Available and Anticipated Number of Awards
Currently reads:
NHLBI intends to commit $675,000 in FY 2015, $2,175,000 in FY 2016, $3,000,000 in FY 2017, and $1,500,000 in FY 2018.
NHLBI intends to fund up to 3 new Phase I or Fast-Track SBIR awards in FY 2015, up to 3 new Phase I and 2 new Phase II SBIR awards in FY 2016, and up to 2 new Phase II SBIR awards in FY 2017.
Modified to read:
NHLBI intends to commit $675,000 in FY 2015, $2,175,000 in FY 2016, $0 in FY 2017, $1,500,000 in FY 2018, and $1,500,000 in FY 2019.
NHLBI intends to fund up to 3 new Phase I or Fast-Track SBIR awards in FY 2015, up to 3 new Phase I and 2 new Phase II SBIR awards in FY 2016, and up to 2 new Phase II SBIR awards in FY 2018.
All other aspects of this FOA remain unchanged.
Inquiries
Please direct all inquiries to:
Shimian Zou, PhD
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-435-0074
Email: [email protected]
and Human Services (HHS)
